The latest report by IMARC Group, titled “Neuromodulation Market Report by Technology (Internal Neuromodulation, External Neuromodulation), Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), Application (Parkinson's Disease, Epilepsy, Depression, Dystonia, Pain Management, and Others), and Region 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on the neuromodulation market report.
The global neuromodulation market size reached US$ 7.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032.
Factors Affecting the Growth of the Neuromodulation Industry:
- Increasing Prevalence of Chronic Diseases and Disorders:
The burgeoning prevalence of chronic diseases and disorders, such as chronic pain, epilepsy, Parkinson's disease, and depression, are major factors driving the market growth. In line with this, the increasing utilization of neuromodulation devices, as they offer solutions by directly acting on the nervous system to alleviate symptoms and improve patients' quality of life, is favoring the market growth. Additionally, the growing availability of clinical evidence demonstrating the efficacy and safety of neuromodulation techniques, is enhancing the market growth. In confluence with this, the rising utilization of spinal cord stimulation (SCS) for managing chronic pain conditions that are resistant to conventional therapies, is bolstering the market growth.
- Rapid Technological Advancements and Innovation:
The rapid technological advancements and innovations that focus on developing sophisticated neuromodulation devices that are more efficient, patient-friendly, and capable of targeting specific neural pathways with greater precision are acting as a growth-inducing factor. In line with this, the introduction of wireless devices, rechargeable systems, and devices with advanced programming options that allow for personalized treatment, is supporting the market growth. Moreover, the widespread integration of neuromodulation devices with digital health platforms and software applications for monitoring and adjusting therapy in real-time to enhance the effectiveness and convenience of treatments is anticipated to drive the market growth. Additionally, the development of closed-loop systems, which focus on adjusting the stimulation parameters based on real-time feedback from the nervous system, is catalyzing the market growth.
- Implementation of Favorable Regulatory and Reimbursement Policies:
The imposition of several regulatory initiatives that streamline the approval processes for neuromodulation devices for the treatment of complex neurological conditions is a major factor bolstering the market growth. Furthermore, the establishment of favorable reimbursement policies for neuromodulation procedures, making the therapies more accessible to a wider patient population, is driving the market growth. Apart from this, the increasing adoption of insurance coverage for various neuromodulation therapies, thereby acknowledging their benefits in treating chronic pain and movement disorders, is anticipated to drive the market growth. Besides this, the growing innovation and investment in the neuromodulation industry to ensure that patients have access to life-enhancing treatments is providing an impetus to the market growth.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/neuromodulation-market/requestsample
Competitive Landscape:
The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market.
- Abbott Laboratories
- Bioventus Inc.
- Boston Scientific Corporation
- Helius Medical Technologies
- Integer Holdings Corporation
- LivaNova PLC
- Medtronic plc
- MicroTransponder Inc.
- Neuronetics
- NeuroPace Inc.
- NeuroSigma Inc.
- Nevro Corp.
Neuromodulation Market Report Segmentation:
By Technology:
- Internal Neuromodulation
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Vagus Nerve Stimulation (VNS)
- Sacral Nerve Stimulation (SNS)
- Gastric Electrical Stimulation (GES)
- External Neuromodulation
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Transcranial Magnetic Stimulation (TMS)
- Others
Internal neuromodulation dominated the market share due to its wide application in treating chronic conditions like pain, Parkinson's disease, and urinary incontinence through invasive techniques that provide long-term relief.
By Biomaterial:
- Metallic Biomaterials
- Polymeric Biomaterials
- Ceramic Biomaterials
Metallic biomaterials accounted for the largest market share due to their durability, biocompatibility, and essential role in manufacturing implants used in neuromodulation therapies.
By Application:
- Parkinson's Disease
- Epilepsy
- Depression
- Dystonia
- Pain Management
- Others
Parkinson's disease represented the largest segment reflecting the high prevalence of the disorder across the globe and the effectiveness of neuromodulation treatments like deep brain stimulation in managing its symptoms.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America's dominance in the neuromodulation market is attributed to its advanced healthcare infrastructure, high adoption of innovative neuromodulation technologies, and favorable reimbursement policies.
Global Neuromodulation Market Trends:
The convergence of neuromodulation with artificial intelligence (AI) and machine learning (ML) technologies to enhance the precision, adaptability, and effectiveness of the therapies, is one of the major factors catalyzing the market growth. In addition to this, the exploration of non-invasive neuromodulation techniques, including focused ultrasound and transcranial magnetic stimulation (TMS), that offer a less invasive alternative to traditional implanted devices while potentially reducing risks and making the therapy accessible is fueling the market growth. Furthermore, the expanding application of neuromodulation in treatments for addiction, obesity, and cognitive disorders is opening new opportunities for the market growth.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5722&flag=C
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
